Item

Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): primary analysis of the randomized, phase 3 DESTINY-Gastric04 study

Shitara, K.
; 
Gumus, M.
; 
Pietrantonio, F.
; 
Lonardi, S.
; 
De La Fouchardiere, C.
; 
Coutzac, C.
; 
Dekervel, J.
; 
Hochhauser, D.
; 
Shen, L.
; 
Mansoor, W.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Authors
Shitara, K.
Gumus, M.
Pietrantonio, F.
Lonardi, S.
De La Fouchardiere, C.
Coutzac, C.
Dekervel, J.
Hochhauser, D.
Shen, L.
Mansoor, W.
Liu, B.
Fornaro, L.
Ryu, M. H.
Lee, J.
Souza, F.
Jukofsky, L.
Zhao, Y. M.
Kamio, T.
Zaanan, A.
Van Cutsem, E.
Affiliation
Natl Canc Ctr Hosp East, Kashiwa, Japan Istanbul Medeniyet Univ, Prof Dr Suleyman Yalcin City Hosp, Istanbul, Turkiye Fdn IRCCS Ist Nazl Tumori, Milan, Italy Veneto Inst Oncol IOV IRCCS, Padua, Italy Ctr Leon Berard, Lyon, France Ctr Leon Berard, Dept Med Oncol, Lyon, France Univ Hosp Gasthuisberg, Leuven, Belgium Univ Leuven, Leuven, Belgium Univ Coll Hosp, Macmillan Canc Ctr, London, England Peking Univ Canc Hosp & Inst, Dept GI Oncol, State Key Lab Holist Integrat Management Gastroint, Beijing, Peoples R China Christie NHS Fdn Trust, Manchester, England Shandong Canc Hosp, Jinan, Peoples R China Azienda Osped Univ Pisana, Pisa, Italy Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea Samsung Med Ctr, Seoul, South Korea Daiichi Sankyo Inc, Basking Ridge, NJ USA Hop Europeen Georges Pompidou, Dept Digest Oncol, Paris, France
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Shitara K, Gumus M, Pietrantonio F, Lonardi S, De La Fouchardiere C, Coutzac C, et al. Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. JOURNAL OF CLINICAL ONCOLOGY. 2025 JUN 10;43(17_SUPPL):LBA4002-LBA. PubMed PMID: WOS:001511752700001. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/628211
Embedded videos